+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Research Antibodies & Reagents Market by Type (Antibodies, Reagents), Source (Mouse-Derived, Rabbit-Derived, Rat-Derived), Technology, Disease Area, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666480
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Research Antibodies & Reagents Market grew from USD 18.55 billion in 2024 to USD 20.79 billion in 2025. It is expected to continue growing at a CAGR of 12.00%, reaching USD 36.62 billion by 2030.

In today’s dynamic biomedical landscape, the antibodies and reagents market continues to gain prominence as a pivotal research and diagnostic resource. This report lays the foundation by examining the intricate interplay of scientific progress, investment trends, and breakthrough technologies that are reshaping the industry. The research presented delves into market drivers, innovative product lines, and the evolving requirements of stakeholders to offer a comprehensive view of the current market dynamics.

Rapid advancements in immunology and molecular biology have spurred the need for high-quality antibodies and an array of supportive reagents to address complex biomedical challenges. Stakeholders from academic research institutions, biopharmaceutical companies, and contract research organizations are increasingly relying on these tools to unlock new insights, drive therapeutic discoveries, and streamline diagnostic procedures. By integrating data-driven analysis with a critical assessment of historical trends, this report highlights the transformative journey the sector has undergone over the past few years.

The narrative presented offers an in-depth exploration of market trends, illuminating key developments in product innovation, supply chain evolution, and regulatory landscapes. It prepares the reader to navigate a rapidly changing environment where precision, reliability, and technological innovation serve as the cornerstones for future growth. The insights herein are aimed at equipping decision-makers with actionable intelligence to harness emerging opportunities within this vibrant market space.

Transformative Shifts in the Antibodies & Reagents Landscape

The past decade has witnessed a series of transformative shifts in the antibodies and reagents market, driven by technological convergence and a heightened global focus on personalized medicine. Traditional research methods have been progressively supplemented by high-throughput screening techniques and automation, fostering greater efficiency and precision in data gathering. This evolution has redefined industry norms and forced a reconsideration of long-established strategies in product development and quality assurance.

Investment in research infrastructures, particularly in the realm of recombinant antibody technology and next-generation reagent formulations, has led to significant improvements in reliability and specificity. Furthermore, evolving regulatory frameworks have prompted manufacturers to elevate quality standards and innovate with agility. These developments have not only expanded the market’s capacity to meet increasing demand but have also bolstered confidence among end users who depend on cutting-edge solutions for critical diagnostic and therapeutic applications.

Modern tools such as digital data platforms and advanced analytics are now central to market evolution, enabling real-time performance monitoring and offering insights that drive refinement across the product life cycle. The industry is experiencing a move towards integrative approaches that combine traditional immunoassays with breakthrough digital and biotechnological innovations. This synergistic transformation is helping stakeholders to overcome conventional bottlenecks, enhancing overall responsiveness to emerging global health challenges.

Key Segmentation Insights in the Antibodies & Reagents Market

Understanding the market structure begins with a close examination of its segmentation, which provides a robust framework for analyzing different product categories and their applications. The market is primarily segmented based on type, source, technology, disease area, application, and end user. Under the type segmentation, the focus is on antibodies and reagents. Antibodies are further analyzed by their nature, including primary antibodies that consist of monoclonal and polyclonal types, recombinant antibodies which represent a leap forward in terms of customization and specificity, and secondary antibodies that support various detection methods. In parallel, reagents encompass a broad spectrum of compounds ranging from buffers and solutions critical for cell culture experiments to specialized chemicals such as enzymes, fixatives, and stains. This category also extends to nucleic acids, probes, peptides, proteins, and even vectors and plasmids that are crucial for gene editing and molecular cloning activities.

When segmented by source, the market distinguishes between products derived from mouse, rabbit, or rat, each offering unique advantages based on the biological system used for antibody production. In addition, technology-based segmentation provides insights into procedural approaches such as enzyme-linked immunosorbent assays, flow cytometry, immunofluorescence, immunohistochemistry, immunoprecipitation, lateral flow assays, mass spectrometry, and Western blotting. Notably, enzyme-linked immunosorbent assays are dissected further into competitive and sandwich assays, highlighting the nuances of assay design and application.

Further segmentation by disease area brings focus to key therapeutic spaces including cardiology, infectious diseases, neurology, and oncology where each domain is examined in depth. For instance, the cardiology segment investigates conditions like atherosclerosis and hypertension, whereas infectious diseases explore both bacterial and viral infections. Neurology delves into the challenges posed by Alzheimer’s and Parkinson’s diseases, and oncology examines critical concerns in breast cancer and lung cancer research. From an application perspective, market segmentation spans diagnostic, drug development, research and development, and therapeutics, with the research and development sub-segment delving into areas such as genomics and proteomics. Lastly, segmentation based on end user classifies the market into academic research institutions, biopharmaceutical companies, and contract research organizations, all of which rely on these tools to push the boundaries of scientific exploration and medical innovation.

Based on Type, market is studied across Antibodies and Reagents. The Antibodies is further studied across Primary Antibodies, Recombinant Antibodies, and Secondary Antibodies. The Primary Antibodies is further studied across Monoclonal Antibodies and Polyclonal Antibodies. The Reagents is further studied across Buffers & Solutions, Cell Culture Reagents, Cytokines & Growth Factors, Detection Reagents, Enzymes, Fixatives & Stains, Nucleic Acids, Probes, Proteins & Peptides, and Vectors & Plasmids.

Based on Source, market is studied across Mouse-Derived, Rabbit-Derived, and Rat-Derived.

Based on Technology, market is studied across Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Lateral Flow Assays, Mass Spectrometry, and Western Blotting. The Enzyme-Linked Immunosorbent Assay is further studied across Competitive Assays and Sandwich Assays.

Based on Disease Area, market is studied across Cardiology, Infectious Diseases, Neurology, and Oncology. The Cardiology is further studied across Atherosclerosis and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Neurology is further studied across Alzheimer's Disease and Parkinson's Disease. The Oncology is further studied across Breast Cancer and Lung Cancer.

Based on Application, market is studied across Diagnostic, Drug Development, Research & Development, and Therapeutics. The Research & Development is further studied across Genomics and Proteomics.

Based on End User, market is studied across Academic Research Institutions, Biopharmaceutical Companies, and Contract Research Organizations.

Key Regional Insights: A Global Perspective

Regional dynamics provide a multifaceted perspective on the antibodies and reagents market, reflecting varying economic conditions, regulatory frameworks, and prevalent research practices. Analysis across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscores the heterogeneous nature of market growth and provides nuanced insights into localized trends. In the Americas, robust funding for biomedical research and the presence of cutting-edge institutions have spurred an increased adoption rate of novel antibodies and tailor-made reagents. This region’s dynamic environment is further bolstered by strategic alliances between academic centers and private enterprises.

The Europe, Middle East & Africa region embodies a blend of mature markets and emerging research hubs. Here, rigorous regulatory standards coupled with a long history of scientific innovation drive demand for high-quality reagents that meet stringent criteria. Collaborative research initiatives, particularly those bridging academic and industry expertise, have seen substantial growth in this region. Meanwhile, the Asia-Pacific territory is rapidly emerging as a powerhouse in the global landscape. Benefitting from accelerated industrialization, sustained government investments in science and technology, and a burgeoning base of skilled researchers, the region’s market trajectory is characterized by a rapid embrace of advanced antibody and reagent technologies. These regional insights are pivotal, as they offer decision-makers an opportunity to tailor strategies that align with specific market nuances and leverage regional strengths to optimize investment and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Growth in the Market

The antibodies and reagents market is significantly shaped by a diverse array of companies that have established themselves as innovators and reliable suppliers in the sector. Prominent players such as Abbott Laboratories and Agilent Technologies Inc. have continuously pushed the envelope with advanced formulations and breakthrough technologies that are setting new benchmarks in research quality. Other industry leaders including Alpha Teknova, Inc. and Atlas Antibodies AB have contributed to this vibrant ecosystem by offering novel solutions that address complex research needs. The presence of Avantor, Inc. and BASF SE highlights the integration of chemical and biotechnological expertise, ensuring that reagents maintain the highest levels of consistency and performance.

Organizations such as Becton, Dickinson and Company and Bio-Rad Laboratories, Inc. have built robust portfolios by delivering instruments and reagents that complement evolving assay technologies. Companies like Bio-Techne Corporation and bioMérieux S.A. have also carved out significant market segments by focusing on specialized and high-demand products, while Cardinal Health, Inc. and Cell Signaling Technology, Inc. continue to grow their market presence by leveraging strategic partnerships and dedicated research pipelines. Furthermore, the commitment shown by research-driven entities such as Charles River Laboratories International, Inc. and Danaher Corporation underscores the industry’s pivot towards integrating technology and biological science. This trend is complemented by niche but influential companies including Dovetail Genomics LLC, Enzo Life Sciences, Inc., F. Hoffmann-La Roche Ltd., and FUJIFILM Holdings Corporation that provide targeted solutions to meet evolving scientific needs.

Other key players such as GenScript Biotech Corporation, Honeywell International Inc., Illumia, Inc., ImmunoPrecise Antibodies Ltd., Leinco Technologies, Inc., and LifeSpan BioSciences, Inc. further enrich the landscape with innovations that address specialized research demands. LobaChemie Pvt. Ltd. and Lonza Group Ltd. illustrate the global breadth of the market, while Merck KGaA, Omega Bio-tek, Inc., PerkinElmer, Inc., QIAGEN N.V., and Randox Laboratories Ltd. contribute to both market depth and geographical diversity. Notably, Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological, Inc., Thermo Fisher Scientific, Inc., Tokyo Chemical Industry Co., Ltd., and Tosoh Corporation round out a list of companies that continue to influence the market with their scientific rigor and broad product portfolios. The interplay between these companies fosters an environment of continuous innovation and intense competition, driving the industry toward higher standards and expanded applications.

The report delves into recent significant developments in the Research Antibodies & Reagents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Alpha Teknova, Inc., Atlas Antibodies AB, Avantor, Inc., BASF SE, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMérieux S.A., Cardinal Health, Inc., Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Danaher Corporation, Dovetail Genomics LLC, Enzo Life Sciences, Inc., F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GenScript Biotech Corporation, Honeywell International Inc., Illumia, Inc., ImmunoPrecise Antibodies Ltd., Leinco Technologies, Inc., LifeSpan BioSciences, Inc., LobaChemie Pvt. Ltd., Lonza Group Ltd., Merck KGaA, Omega Bio-tek, Inc., PerkinElmer, Inc., QIAGEN N.V., Randox Laboratories Ltd., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological, Inc., Thermo Fisher Scientific, Inc., Tokyo Chemical Industry Co., Ltd., and Tosoh Corporation.

Actionable Recommendations for Industry Leaders in the Antibodies & Reagents Sphere

Industry leaders aiming to capitalize on the transformative trends within the antibodies and reagents market must adopt proactive strategies that align with both technological advancements and evolving regulatory landscapes. A key recommendation is to invest in research and development initiatives that integrate digital analytics with traditional laboratory research. By streamlining the innovation process, companies can shorten product development cycles and respond to market demand with greater agility.

Furthermore, fostering collaborations with academic research institutions and contract research organizations can yield insights that drive product customization and regional market adaptation. Embracing flexible manufacturing processes and diversifying product portfolios to include both traditional assay systems and advanced recombinant technologies will serve as a competitive advantage. Leaders should also focus on enhancing data transparency and quality control measures to build trust and ensure consistent performance in diagnostic and therapeutic applications. This strategic approach will not only reinforce market positioning but also stimulate long-term growth by addressing emerging needs in global healthcare.

Integrating Innovation, Insight, and Impact

The antibodies and reagents market stands at a critical juncture, propelled by increasingly sophisticated technological capabilities and expanding research requirements. This comprehensive analysis has synthesized key trends, detailed segmentation insights, regional dynamics, and the influence of major industry players to paint a vivid picture of a market poised for growth and innovation. Stakeholders are encouraged to harness this intelligence as a roadmap for navigating competitive landscapes and advancing scientific discoveries.

Ultimately, the journey ahead is one of integrating deep scientific insight with agile business strategies. In doing so, industry participants will be well positioned to lead the way in driving transformative change that has far-reaching impacts on healthcare, research, and beyond.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing government funding initiatives for antibodies research purposes
5.1.1.2. Rising prevalence of chronic diseases driving the adoption of targeted antibody-based treatments
5.1.1.3. Continuous rise in research and development spending by pharmaceutical and biotechnology companies
5.1.2. Restraints
5.1.2.1. High initial costs associated with research antibodies and reagents production
5.1.3. Opportunities
5.1.3.1. Increasing development and adoption of environmentally friendly reagents
5.1.3.2. Technological advancements in antibody engineering
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements to ensure the safety and efficacy of the antibodies and reagents
5.1.4.2. Ethical and biological concerns over production of antibodies
5.2. Market Segmentation Analysis
5.2.1. Type: Rising demand for reagents for conducting and supporting biochemical reactions
5.2.2. End user: Growing adoption of research antibodies & reagents across biopharmaceutical companies for drug discovery and validation processes.
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Research Antibodies & Reagents Market, by Type
6.1. Introduction
6.2. Antibodies
6.2.1. Primary Antibodies
6.2.1.1. Monoclonal Antibodies
6.2.1.2. Polyclonal Antibodies
6.2.2. Recombinant Antibodies
6.2.3. Secondary Antibodies
6.3. Reagents
6.3.1. Buffers & Solutions
6.3.2. Cell Culture Reagents
6.3.3. Cytokines & Growth Factors
6.3.4. Detection Reagents
6.3.5. Enzymes
6.3.6. Fixatives & Stains
6.3.7. Nucleic Acids
6.3.8. Probes
6.3.9. Proteins & Peptides
6.3.10. Vectors & Plasmids
7. Research Antibodies & Reagents Market, by Source
7.1. Introduction
7.2. Mouse-Derived
7.3. Rabbit-Derived
7.4. Rat-Derived
8. Research Antibodies & Reagents Market, by Technology
8.1. Introduction
8.2. Enzyme-Linked Immunosorbent Assay
8.2.1. Competitive Assays
8.2.2. Sandwich Assays
8.3. Flow Cytometry
8.4. Immunofluorescence
8.5. Immunohistochemistry
8.6. Immunoprecipitation
8.7. Lateral Flow Assays
8.8. Mass Spectrometry
8.9. Western Blotting
9. Research Antibodies & Reagents Market, by Disease Area
9.1. Introduction
9.2. Cardiology
9.2.1. Atherosclerosis
9.2.2. Hypertension
9.3. Infectious Diseases
9.3.1. Bacterial Infections
9.3.2. Viral Infections
9.4. Neurology
9.4.1. Alzheimer's Disease
9.4.2. Parkinson's Disease
9.5. Oncology
9.5.1. Breast Cancer
9.5.2. Lung Cancer
10. Research Antibodies & Reagents Market, by Application
10.1. Introduction
10.2. Diagnostic
10.3. Drug Development
10.4. Research & Development
10.4.1. Genomics
10.4.2. Proteomics
10.5. Therapeutics
11. Research Antibodies & Reagents Market, by End User
11.1. Introduction
11.2. Academic Research Institutions
11.3. Biopharmaceutical Companies
11.4. Contract Research Organizations
12. Americas Research Antibodies & Reagents Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Research Antibodies & Reagents Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Research Antibodies & Reagents Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Scenario Analysis
15.3.1. QIAGEN and McGill University partner to advance microbiome research
15.3.2. UTMB awarded USD 46.4 million ReVAMPP grant for pandemic preparedness research
15.3.3. Bio-Rad expands antibody range for enhanced bioanalytical assays
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. RESEARCH ANTIBODIES & REAGENTS MARKET MULTI-CURRENCY
FIGURE 2. RESEARCH ANTIBODIES & REAGENTS MARKET MULTI-LANGUAGE
FIGURE 3. RESEARCH ANTIBODIES & REAGENTS MARKET RESEARCH PROCESS
FIGURE 4. RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2030 (%)
FIGURE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 17. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 19. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 23. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. RESEARCH ANTIBODIES & REAGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 29. RESEARCH ANTIBODIES & REAGENTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESEARCH ANTIBODIES & REAGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RESEARCH ANTIBODIES & REAGENTS MARKET DYNAMICS
TABLE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CELL CULTURE REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CYTOKINES & GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DETECTION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FIXATIVES & STAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEINS & PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VECTORS & PLASMIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MOUSE-DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RABBIT-DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RAT-DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COMPETITIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SANDWICH ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOPRECIPITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 123. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 124. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 126. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 127. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 128. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 129. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 130. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 131. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 133. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 141. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 142. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 143. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 148. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 198. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 199. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 200. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 201. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 203. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 204. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 205. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 206. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 207. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 210. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 214. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 215. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 216. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 218. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 219. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 220. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 221. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 222. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 223. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 225. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 246. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 248. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 249. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 250. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 251. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 252. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 253. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 297. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASS

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Alpha Teknova, Inc.
  • Atlas Antibodies AB
  • Avantor, Inc.
  • BASF SE
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux S.A.
  • Cardinal Health, Inc.
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Dovetail Genomics LLC
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GenScript Biotech Corporation
  • Honeywell International Inc.
  • Illumia, Inc.
  • ImmunoPrecise Antibodies Ltd.
  • Leinco Technologies, Inc.
  • LifeSpan BioSciences, Inc.
  • LobaChemie Pvt. Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Omega Bio-tek, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Randox Laboratories Ltd.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz Biotechnology, Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Tosoh Corporation

Methodology

Loading
LOADING...

Table Information